MedTrace Logo

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

NCT07102901 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 351

Last updated 2025-09-10

No results posted yet for this study

Summary

This is a multicenter, phase 2, open label study to evaluate safety, tolerability and efficacy of SHR2554 combined with other anti-tumor treatments in patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

Conditions

  • Advanced Gastric Cancer
  • Metastatic Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

SHR2554 Tablets

Oral SHR2554 tablets.

DRUG

SHR-A1811 Injection

SHR-A1811 for injection.

DRUG

SHR-A1904 Injection

SHR-A1904 for injection.

DRUG

SHR-1701 Injection

SHR-1701 injection

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-05
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07102901 on ClinicalTrials.gov